Monitor upcoming Phase 1b IPF patient data readout later in 2026, which will be a key catalyst for valuation. The patent strengthens IP position but does not alter near-term financials.
Price Chart
Executive Summary
AgomAb Therapeutics announced the issuance of a U.S. patent (No. 12,577,230) covering the composition of matter for its investigational inhaled drug AGMB-447, providing IP protection through at least 2041. The drug is currently in a Phase 1b trial for idiopathic pulmonary fibrosis (IPF), with patient cohort results expected later in 2026.
Key Facts
- U.S. Patent No. 12,577,230 granted for AGMB-447, covering composition of matter.
- Patent provides U.S. IP protection through at least 2041, excluding potential extensions.
- AGMB-447 is an inhaled, lung-restricted ALK5 inhibitor in Phase 1b development for IPF.
- Positive healthy subject data previously reported; IPF patient data expected later in 2026.
- AGMB-447 is not approved; efficacy and safety not yet established.
Financial Impact
No immediate financial impact disclosed; long-term value depends on clinical success and commercialization.
Risk Factors
- Clinical development risk: AGMB-447 may fail to demonstrate efficacy or safety in IPF patients.
- Forward-looking statements are subject to uncertainties in drug development and IP enforceability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262841 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Insider Buy | $9.26 | awaiting T+5 | — | $8.57 (−7.45%) |
Oct 13, 2026 13d ago | 6-K | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $8.57 (−1.38%) |
Oct 13, 2026 13d ago | Press Release | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $8.57 (−1.38%) |
Oct 1, 2026 25d ago | 6-K | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $8.57 (−0.92%) |
Oct 1, 2026 25d ago | Press Release | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $8.57 (−0.92%) |
Sep 14, 2026 6w ago | 6-K | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $8.57 (−29.52%) |
Sep 14, 2026 6w ago | Press Release | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $8.57 (−29.52%) |
Sep 11, 2026 6w ago | 6-K | $12.28 $11.70 | ▼ −4.72% | ▼ −4.83% | $8.57 (−30.21%) |
Aug 10, 2026 11w ago | 6-K | $14.85 $13.73 | ▼ −7.54% | ▼ −7.14% | $8.57 (−42.29%) |
Jun 23, 2026 17w ago | 6-K | $12.68 $11.87 | ▼ −6.39% | ▼ −8.10% | $8.57 (−32.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers